Assessing Safety of Fibroblast Cell Therapy in Multiple Sclerosis: Hamid Khoja, PhD

Fibroblast cell technology seems to be safe for use in patients with multiple sclerosis (MS) and may offer a unique treatment approach. Hamid Khoja, PhD, chief scientific officer, FibroBiologics, discussed the technology, dubbed CYMS101, and the limited clinical trial that evaluated its safety.

Kohja discussed how patients treated with a 1-time infusion of CYMS101 did not experience any adverse events (AEs), unlike those treated with humanized monoclonal antibodies, although he did note the small scale of the study,

Patients enrolled in the safety study were monitored post-infusion for 4 hours and then at 4-week intervals for complete blood count and blood chemistry, where investigators again did not notice a difference. While experts opted for a single dose in the initial study, in the phase 1/2 clinical trial, multiple doses will be assessed, and investigators will look at multiple concentrations of cells to determine efficacy and safety. According to Khoja, FibroBiologics is aiming for a staggered approach to the clinical trial and anticipates filing an investigational new drug application in the third quarter of 2022.